CD8A and congenital rubella syndrome: Furthermore, factors reshaping the metabolic state of CAR‐Ts are another option in the context of a hostile TME.[142] However, CRS and ICANS still limit the clinical application of CAR‐Ts.[7a] As we discussed earlier, the application of CD8+ CD19‐CAR‐Ts generated from engineered LVs can result in signs of CRS,[98] demonstrating that CAR‐T‐associated toxicity will still be a challenge in in vivo contexts.